Tuesday 22 October 2013 9:13am
A new classification of renal tumours that a leading University of Otago pathologist has helped develop is set to enhance the ability to develop treatments and more accurately predict outcomes for patients. Such tumours are diagnosed in around 510 New Zealanders each year, with numbers projected to rise to 630 by 2016.
Professor Brett Delahunt, from the University of Otago, Wellington Department of Pathology and Molecular Medicine was Chair of the International Society of Urological Pathology (ISUP) Consensus Conference convened in Vancouver in 2012 that resulted in changes to the current WHO classification.
Professor Brett Delahunt
He says the basis of their recommendations is a long-overdue acknowledgement that there are many sorts of kidney cancers, with different genetics, different behaviours and, ultimately, different treatments.
The new classification, combined with a new grading system that focuses on novel criteria, is set to promote a new era in renal tumour diagnosis and treatment, he says.
“This will be the gospel for pathology. Prior to this, guidelines for classification, grading and staging have been seriously out of date.”
He notes that it wasn’t until 1981 that the WHO even classified kidney cancers, and at that point for the first time came up with just two classes: “Renal Cell Carcinoma” and “Other”.
Over the years he has been involved in consensus meetings that have continued to develop this classification, recognising the need to have separate genetic and morphologic criteria. By 2004 there were nine different classes, but even that classification is now recognised as being inadequate, Professor Delahunt says.
In the decade since the last classification, Professor Delahunt has been among those at the forefront of describing the different nuances of kidney cancer, identifying a greater array that has allowed the proper classification and grouping of these tumours.
The ISUP Consensus Conference, which consisted of 133 international experts from 29 different countries, also endorsed a grading system based on novel features in the structure of the cell nucleus. This replaces the Fuhrman grading system used to date that has been highly-criticised for its unclear criteria and debated predictive value.
“Essentially what we have done is abandon Fuhrman and redefined a more objective grading system that has a proven association with outcome.”
The results of the ISUP Consensus Conference have been published in five separate papers in the October 2013 issue of the highly-prestigious American Journal of Surgical Pathology.
For further information contact:
Professor Brett Delahunt
Department of Pathology and Molecular Medicine
University of Otago, Wellington
Tel 64 4 385 5569
Email brett.delahunt@otago.ac.nz
Web www.otago.ac.nz/wellington
A list of Otago experts available for media comment is available elsewhere on this website.
Electronic addresses (including email accounts, instant messaging services, or telephone accounts) published on this page are for the sole purpose of contact with the individuals concerned, in their capacity as officers, employees or students of the University of Otago, or their respective organisation. Publication of any such electronic address is not to be taken as consent to receive unsolicited commercial electronic messages by the address holder.
